VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Matthew Davids On Advances in CLL

Matthew Davids, MD
Published: Wednesday, Feb 18, 2015

 

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances inchronic lymphocytic leukemia (CLL) treatment.

Several novel therapies have been approved recently for CLL, including obinutuzumab, ibrutinib, ofatumumab, and idelalisib. Since many of these novel therapies only elicit a partial response, combining them may be a better plan for developing a deeper, more full response, says Davids. Another benefit of combining these agents is that many of them have non-overlapping toxicities and complementary efficacy.

Davids says in practice, these newly approved agents will be used more in older patients in an attempt to move away from chemotherapy, while a combination of chemo-immunotherapy may be more ideal for younger patients.

 

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances inchronic lymphocytic leukemia (CLL) treatment.

Several novel therapies have been approved recently for CLL, including obinutuzumab, ibrutinib, ofatumumab, and idelalisib. Since many of these novel therapies only elicit a partial response, combining them may be a better plan for developing a deeper, more full response, says Davids. Another benefit of combining these agents is that many of them have non-overlapping toxicities and complementary efficacy.

Davids says in practice, these newly approved agents will be used more in older patients in an attempt to move away from chemotherapy, while a combination of chemo-immunotherapy may be more ideal for younger patients.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x